Analysis of baseline and cisplatin-inducible gene expression in Fanconi anemia cells using oligonucleotide-based microarrays

BMC Blood Disorders

Volumn 2, Issue , 2002, Pages

  Waisfisz, Quinten ^a   Miyazato, Akira ^b   de Winter, Johan P ^a   Liu, Johnson M ^b   Joenje, Hans ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; GROWTH FACTOR; MEMBRANE PROTEIN; MITOMYCIN C; OLIGONUCLEOTIDE; PROTEIN P21; TRANSCRIPTION FACTOR;

ARTICLE; BONE MARROW DEPRESSION; CANCER SUSCEPTIBILITY; CASE REPORT; CELL CYCLE; CELL DAMAGE; CELLULAR DISTRIBUTION; CHROMATIN STRUCTURE; CHROMOSOME DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE EXACERBATION; DNA CROSS LINKING; DNA REPAIR; DOSE RESPONSE; DRUG EXPOSURE; FANCONI ANEMIA; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; UNINDEXED SEQUENCE; UPREGULATION; WESTERN BLOTTING;

EID: 0037710296     PISSN: 14712326     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2326-2-5     Document Type: Article

References (42)

1. Auerbach AD, Buchwald M, Joenje H: Fanconi Anemia. In: The Genetic Basis of Human Cancer (Edited by: Vogelstein B, Kinzler KW) New York, McGraw-Hill 1998, 317-332
2. Strathdee CA, Gavish H, Shannon WR, Buchwald M: Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992, 356:763-767
3. The Fanconi anaemia/breast cancer consortium: Positional cloning of the Fanconi anaemia group A gene. Nat Genet 1996, 14:324-328
4. Lo ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DF, Savoia A, et al: Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996, 14:320-323
5. de Winter JP, Waisfisz Q, Rooimans MA, van Berkel CG, Bosnoyan-Collins L, Alon N, Carreau M, Bender O, Demuth I, Schindler D, et al: The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet 1998, 20:281-283
6. de Winter JP, Rooimans MA, van Der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y, Waisfisz Q, Pronk JC, et al: The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000, 24:15-16
7. de Winter JP, Leveille F, van Berkel CG, Rooimans MA, van Der Weel L, Steltenpool J, Demuth I, Morgan NV, Alon N, Bosnoyan-Collins L, et al: Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet 2000, 67:1306-1308
8. Timmers C, Taniguchi T, Hejna J, Reifsteck C, Lucas L, Bruun D, Thayer M, Cox B, Olson S, D'Andrea AD, et al: Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 2001, 7:241-248
9. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609
10. Fagerlie SR, Diaz J, Christianson TA, McCartan K, Keeble W, Faulkner GR, Bagby GC: Functional correction of FA-C cells with FANCC suppresses the expression of interferon gamma-inducible genes. Blood 2001, 97:3017-3024
11. Li Y, Youssoufian H: MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest 1997, 100:2873-2880
12. Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001, 2:446-457
13. Grompe M, D'Andrea A: Fanconi anemia and DNA repair. Hum Mol Genet 2001, 10:2253-2259
14. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001, 7:249-262
15. Zdzienicka MZ, Arwert F: Breast cancer and Fanconi anemia: what are the connections? Trends Mol Med 2002, 8:458-460
16. Latt SA, Kaiser TN, Lojewski A, Dougherty C, Juergens L, Brefach S, Sahar E, Gustashaw K, Schreck RR, Powers M, et al: Cytogenetic and flow cytometric studies of cells from patients with Fanconi's anemia. Cytogenet Cell Genet 1982, 33:133-138
17. Kruyt FA, Dijkmans LM, van den Berg TK, Joenje H: Fanconi anemia genes act to suppress a cross-linker-inducible p53-independent apoptosis pathway in lymphoblastoid cell lines. Blood 1996, 87:938-948
18. Kruyt FA, Dijkmans LM, Arwert F, Joenje H: Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase. Cancer Res 1997, 57:2244-2251
19. Kupfer GM, D'Andrea AD: The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. Blood 1996, 88:1019-1025
20. Heinrich MC, Hoatlin ME, Zigler AJ, Silvey KV, Bakke AC, Keeble WW, Zhi Y, Reifsteck CA, Grompe M, Brown MG, et al: DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 1998, 91:275-287
21. Akkari YM, Bateman RL, Reifsteck CA, D'Andrea AD, Olson SB, Grompe M: The 4N Cell Cycle Delay in Fanconi Anemia Reflects Growth Arrest in Late S Phase. Mol Genet Metab 2001, 74:403-412
22. Sala-Trepat M, Rouillard D, Escarceller M, Laquerbe A, Moustacchi E, Papadopoulo D: Arrest of S-phase progression is impaired in Fanconi anemia cells. Exp Cell Res 2000, 260:208-215
23. Centurion SA, Kuo HR, Lambert WC: Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA crosslinking agent. Exp Cell Res 2000, 260:216-221
24. Zhao R, Rabo YB, Egyhazi S, Andersson A, Edgren MR, Linder S, Hansson J: Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line. Anticancer Drugs 1995, 6:657-668
25. Rabo YB, Shoshan MC, Linder S, Hansson J: Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light. Int J Cancer 1996, 65:821-826
26. Ballester A, Perez C, Aller P, Mata F: Differentiation of U-937 promonocytic cells with mitomycin C or cis-diamminedichloroplatinum II. Int J Cancer 1996, 65:791-795
27. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998, 273:23419-23425
28. Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG: DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1997, 39:245-253
29. Young RA: Biomedical discovery with DNA arrays. Cell 2000, 102:9-15
30. Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra AB, Veerman AJ, van Weel M, Pauli RM, Shahidi NT, Dokal I, Roberts I, et al: Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997, 5:137-148
31. Kruyt FA, Waisfisz Q, Dijkmans LM, Hermsen MA, Youssoufian H, Arwert F, Joenje H: Cytoplasmic localization of a functionally active Fanconi anemia group A-green fluorescent protein chimera in human 293 cells. Blood 1997, 90:3288-3295
32. Joenje H, Lo ten Foe JR, Oostra AB, van Berkel CG, Rooimans MA, Schroeder-Kurth T, Wegner RD, Gille JJ, Buchwald M, Arwert F: Classification of Fanconi anemia patients by complementation analysis: evidence for a fifth genetic subtype. Blood 1995, 86:2156-2160
33. Ishida R, Buchwald M: Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res 1982, 42:4000-4006
34. Waisfisz Q, de Winter JP, Kruyt FA, de Groot J, van der Weel L, Dijkmans LM, Zhi Y, Arwert F, Scheper RJ, Youssoufian H, et al: A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci U S A 1999, 96:10320-10325
35. Burczynski ME, McMillian M, Ciervo J, Li L, Parker JB, Dunn RT 2nd, Hicken S, Farr S, Johnson MD: Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 2000, 58:399-415
36. Huang Q, Dunn RT 2nd, Jayadev S, DiSorbo O, Pack FD, Farr SB, Stoll RE, Blanchard KT: Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 2001, 63:196-207
37. Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815
38. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, et al: Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996, 86:159-171
39. Xu Y, Baltimore D: Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 1996, 10:2401-2410
40. Weeda G, Donker I, de Wit J, Morreau H, Janssens R, Vissers CJ, Nigg A, van Steeg H, Bootsma D, Hoeijmakers JH: Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr Biol 1997, 7:427-439
41. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, et al: The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85:1009-1023
42. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR: Involvement of Brca2 in DNA repair. Mol Cell 1998, 1:347-357